🌐 Ce contenu est affiché en allemand. La traduction arrive bientôt.

Tzield (Teplizumab)

zm - Zahnärztliche Mitteilungen

Tzield is an immunomodulatory therapy approved by the FDA for delaying the progression from prediabetes (stage 2) to manifest type 1 diabetes (stage 3) in adults and pediatric patients aged 8 years and older. The medication binds to specific immune system cells and delays progression to stage 3 type 1 diabetes by deactivating immune cells that attack insulin-producing cells while increasing the proportion of cells that help mitigate immune response. Tzield is administered as an intravenous infusion once daily over 14 consecutive days.

Informations produit

Fabricant zm - Zahnärztliche Mitteilungen

Plus de produits

Plus de zm - Zahnärztliche Mitteilungen (70) Plus de Immunomodulatory Therapy (1)

Des informations ou fichiers vous manquent ?